Introduction {#s1}
============

Parkinson's disease (PD) is the second most common neurodegenerative disorder with a prevalence of between 1% and 4% in over-60-year-olds ([@B96]). The diagnosis of PD currently depends on the identification of motor clinical features, including rest tremor, rigidity and bradykinesia. In addition, patients with PD develop a wide range of non-motor manifestations including cognitive impairment and dementia, mood and sleep disturbances, sensory abnormalities and autonomic nervous system dysfunction ([@B76]). It has been estimated that the first motor signs appear when 50% to 80% of dopaminergic neurons in the substantia nigra pars compacta have been lost ([@B21]). Thus, by the time of diagnosis, brain injury has been ongoing for years and any attempt at neuroprotection at this stage might be unsuccessful. Great efforts are being made to detect markers of neuronal dysfunction early in the course of the disease ([@B77]). In relation to this, it is increasingly recognized that non-motor symptoms not only accompany but also precede motor signs in PD ([@B76]). This is consistent with the Braak PD staging system, which suggests that α-synuclein deposition starts in areas involved in sleep regulation, olfaction or autonomic function before affecting the basal ganglia or cerebral cortex ([@B15]). The array of premotor symptoms might help to identify patients at high risk of developing α-synuclein-mediated neurodegenerative diseases, such as PD, dementia with Lewy bodies (DLB) or multiple system atrophy (MSA).

While the mechanisms for motor impairment are fairly well established, the neuroanatomical and molecular substrates for non-motor manifestations are far from clear. Current evidence suggests that neurotransmitters, such as acetylcholine, serotonin, noradrenaline, glutamate and gamma-aminobutyric acid (GABA), play an important role in the pathophysiology of PD ([@B84]). GABA is the main inhibitory neurotransmitter in the central nervous system (CNS), acts through GABA~A~ and GABA~B~ receptors, and is primarily released by local interneurons to regulate cortical and subcortical microcircuits ([**Figures 1A, B**](#f1){ref-type="fig"}). GABAergic signaling modulates a wide range of physiological functions, including sensory perception, information processing and cognition. In patients with PD, GABAergic dysregulation has been observed in the basal ganglia *postmortem* and *in vivo* with magnetic resonance spectroscopy ([@B58]; [@B26]; [@B70]). Recently, it has been shown that striatal dopaminergic axons co-release GABA ([@B94]; [@B95]), which suggests that dopaminergic neurodegeneration could lead to GABA decline in basal ganglia circuits ([@B70]). Considering that GABAergic networks regulate calcium-mediated mechanisms, like mitochondrial function and oxidative stress, loss of GABA inhibitory tone would facilitate accumulation of abnormal levels of intracellular calcium, triggering neurodegenerative processes. Consistent with this idea, it has been shown that GABA agonists, such as Baclofen or Bumetadine, relieve motor symptoms and protect dopaminergic cell bodies in mice models of PD ([@B40]; [@B63]). Nonetheless, GABAergic alterations might go beyond the basal ganglia. Unfortunately, few studies have investigated how GABAergic or other neurotransmitter systems may induce or modulate non-motor symptoms of PD. Identifying the separate role of each pathway may allow us to develop novel pharmacological compounds targeted to specific symptoms. Seeking to provide up-to-date information about the role of the GABAergic system, in this Mini Review, we focus on its ability to explain some of the non-motor manifestations that appear early in PD ([**Table 1**](#T1){ref-type="table"}).

![The GABAergic system and non-motor symptoms in Parkinson's Disease. **(A)** GABA receptors. The inhibitory neurotransmitter GABA acts through ionotropic GABA~A~ receptor or metabotropic GABA~B~ receptor to reduce the membrane potential. The activation of GABA~A~ receptors allows chloride (Cl^-^) entry into the cytoplasm, while GABA~B~ receptor activation leads to a cellular cascade resulting in calcium (Ca^2+^) channel deactivation and potassium (K^+^) channel opening. **(B)** Schematic representation of cortical and subcortical local microcircuit organization of GABAergic cells. Inhibitory GABAergic cells are primarily local projecting neurons with a broad array of anatomical and physiological properties. The effect resulting from the inhibition exerted by GABAergic cells depends on their sensitivity to incoming stimuli, their firing properties and the subcellular domain of excitatory cells targeted by each interneuron. The diversity of GABAergic cells provides the brain with extensive computational power to regulate sensory and cognitive processes. **(C)** Brain areas associated with non-motor symptoms in Parkinson's disease. Each color corresponds to a specific non-motor symptom and the associated area of the presumed GABAergic dysfunction.](fphar-10-01294-g001){#f1}
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Evidence of the involvement of GABAergic neurotransmission in early non-motor symptoms of Parkinson's disease.

  Non-motor symptom               Evidence of GABAergic inhibitory deficit
  ------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  REM sleep behavior disorder     GABAergic cells in the ventral medulla are dysfunctional ^†^ ([@B17])
  Olfactory loss                  Tonic inhibition exerted by interneurons regulates odor detection ([@B75]; [@B89]; [@B4])
  Visual perception alterations   GABAergic depletion in the retina changes contrast sensitivity ^†^ ([@B44])
                                  GABA antagonism in visual cortex decreases stimulus orientation and direction selectivity ^†^ ([@B54])
                                  GABA levels in visual cortex are predictive of visuospatial abilities \* ([@B22])
                                  Visual hallucinations are associated with decreased occipital GABA in PD ([@B34]) and with the loss of postsynaptic GABA markers in DLB \*\* ([@B56])
  Cognitive impairment            GABA transcriptional changes in the frontal cortex \*\* ([@B85])
                                  Levels of PV and GAD67 mRNA expression are low in the frontal cortex \*\* ([@B60]; [@B61])
  Anxiety and depression          GABA~A~ receptor positive modulators are anxiolytic and antidepressant, while negative modulators produce anxiogenic and depressive-like effects ^†,\*^ ([@B53]; [@B67])
                                  GABA receptor dysfunction is linked to anxiety and depression-like behaviors ^†^ ([@B53])
  Gastrointestinal symptoms       GABA regulates the mobility and inflammatory responses of the gastrointestinal tract ^\#^ (Auteri et al., 2005a; Auteri et al 2005b; [@B52])

^†^Studies conducted in animal models, ^\#^physiological function, \* in healthy controls, \*\* in patients with Parkinson's disease (PD) or dementia with Lewy bodies (DLB).

REM Sleep Behavior Disorder and Pontine GABAergic Cell Dysfunction in PD {#s2}
========================================================================

Sleep disturbances are the most common non-motor manifestations of PD, with wide variability in the reported prevalence (66% to 98%) ([@B37]). Sleep-related abnormalities in PD include insomnia, sleep fragmentation, restless legs syndrome, excessive daytime sleepiness and rapid eye movement (REM) sleep behavior disorder (RBD), among others. Some sleep abnormalities occur in early stages of the disease, even during the prodromal phase, including RBD ([@B48]), restless legs syndrome ([@B103]) and excessive daytime sleepiness ([@B3]). Nonetheless, only idiopathic RBD (iRBD) has consistently shown to be an early predictor of the development of PD ([@B49]) ([@B77]).

RBD is a parasomnia characterized by the loss of the normal muscle atonia of REM sleep. The diagnostic hallmark is excessive electromyographic activity during REM sleep as documented by polysomnography ([@B33]). Patients with RBD report the enactments of dreams, including kicking, punching or talking. In the absence of other neurological signs or CNS lesions, patients with iRBD are at high risk of developing α-synuclein-mediated neurodegenerative diseases in the years following the diagnosis ([@B45]). It has also been suggested that the presence of RBD in PD patients is associated with an aggressive phenotype, these patients showing a higher density of α-synuclein aggregates ([@B59]).

Therefore, in recent years, special attention has been paid to PD-related non-motor manifestations and symptom progression in iRBD patients, seeking to find novel biomarkers of PD. Although the precise pathophysiological mechanisms for iRBD have not been fully determined, iRBD seems to be attributable to neurochemical imbalances in sleep regulatory systems ([@B14]). Previous studies have pointed toward a significant and specific neurodegeneration of GABA or glycine-containing neurons in the ventral medulla, such as in the nucleus raphe magnus and the ventral gigantocellular, alpha gigantocellular and lateral paragigantocellular reticular nuclei that directly project to spinal motor neurons to produce atonia during REM sleep ([@B47]) ([**Figure 1C**](#f1){ref-type="fig"}). This hypothesis is supported by preclinical studies in transgenic mice that exhibit an RBD phenotype when glycine and GABA receptor function is impaired ([@B17]). Moreover, allosteric agonists that bind at the α/γ subunit interface of GABA~A~ receptors, i.e., benzodiazepines, including clonazepam, triazolam or alprazolam, are the first-line therapy in iRBD ([@B7]), and the effectiveness of this treatment could be explained by GABAergic neurotransmission disruption in prodromal stages of PD.

Olfactory Loss and Its Relationship With GABAergic Neurotransmission in PD {#s3}
==========================================================================

Olfactory dysfunction is observed in more than 90% of PD patients ([@B23]), frequently precedes the onset of motor symptoms ([@B28]; [@B83]; [@B79]), and predicts the early conversion of iRBD to PD or DLB ([@B64]; [@B30]). The mechanisms responsible for olfactory dysfunction in PD are currently unknown. Magnetic resonance imaging studies have shown significantly smaller olfactory bulb volumes in patients with PD than controls ([@B16]; [@B62]; [@B92]), although other authors failed to find such differences ([@B6]). Axonal and myelin damage of olfactory tracts has also been observed using diffusor-tensor imaging ([@B88]; [@B87]). These results have been confirmed by *postmortem* analysis of olfactory bulbs, in which global glomerular voxel volume was found to be smaller in five PD cases than six healthy controls ([@B105]). Moreover, hyposmia has been related to pathological changes in other areas of the olfactory system, such as the anterior olfactory nucleus or basolateral nucleus of the amygdala ([@B73]; [@B43]). On the other hand, sensory perception disturbances might represent subtle alterations of normal functioning that precede neuronal degeneration. Changes in network connectivity of brain structures related to olfaction have already been described ([@B102]; [@B13]; [@B101]), and these functional abnormalities may arise from iron and sodium deposition ([@B38]).

The limited literature about the precise anatomy and physiology of the human olfactory bulb makes it difficult to assess the mechanisms related to olfactory dysfunction in humans. In this regard, animal studies provide a wealth of knowledge, as the olfactory bulb of rodents has been well characterized. It has been shown that interneurons---GABA-releasing cells---are essential for odor detection, and functionally distinct GABAergic circuits within the olfactory bulb of rodents play different roles in olfactory coding. The tonic inhibition exerted by these cells is thought to regulate the sensitivity of odor detection and odor perception in the mammalian brain ([@B75]; [@B89]; [@B4]) ([**Figure 1C**](#f1){ref-type="fig"}). Even though animal findings suggest that interneuron connectivity is the major determinant of odor perception, whether the loss of inhibitory synapses contributes to olfactory changes in PD in humans needs further research.

Visual Disturbances {#s4}
===================

Among primary visual functions, low-contrast visual acuity, contrast sensitivity and color vision are typically affected in PD ([@B100]). Patients with drug-naïve PD or iRBD also show decreased contrast sensitivity ([@B82]; [@B65]), and abnormal color vision discrimination has been described in iRBD, these patients having a 3-fold higher risk of conversion ([@B78]). Nevertheless, color discrimination is not consistently impaired in the early stages of PD, indicating that color vision abnormalities may represent a specific PD phenotype ([@B99]). Indeed, Postuma and colleagues reported that abnormal color vision in iRBD was a stronger predictor of primary dementia than parkinsonism ([@B78]), which is in line with findings in PD, RBD increasing the risk of cognitive decline ([@B72]). Patients with iRBD or *de novo* PD also display visuoconstructional and visuoperceptual disturbances that may be related to non-dopaminergic impairment ([@B31]; [@B36]; [@B1]; [@B65]; [@B27]; [@B57]; [@B71]).

*In vivo* neuroimaging studies in newly diagnosed and drug-naïve PD patients have detected structural alterations in the visual pathway, ranging from thinning of inner retinal layers to increased optic radiation mean diffusivity and reduced visual cortical volumes ([@B8]; [@B5]; [@B68]), which might explain some visual disturbances. There is, however, a growing body of evidence highlighting the role of GABA in perceptual aspects of vision.

Retinal amacrine cells co-release dopamine and GABA and the degeneration of these specialized cells has been suggested to cause primary visual dysfunction, although this hypothesis has not been confirmed ([@B69]). In line with this, pharmacological depletion of endogenous retinal GABA with allylglycine induces changes in contrast sensitivity ([@B44]). On the other hand, animal studies have shown that GABA~A~ receptor antagonist infusion in cat primary visual cortex decreases selectivity for stimulus orientation and direction, but not contrast sensitivity ([@B54]). More recently, it has been observed that GABA levels measured by magnetic resonance spectroscopy are strong predictors of visuospatial abilities in healthy adults ([@B22]), and increasing GABA activity with systemic midazolam injections decreases visual sensitivity, preferentially affecting medium-to-high spatial frequencies and low temporal frequencies ([@B12]). Additionally, higher GABA concentrations in the visual cortex, as well as administration of the GABA agonist lorazepam, induce slower perceptual dynamics ([@B98]).

These findings suggest that GABA signaling plays a central role in visual perception and a disturbance of this circuit at any level of the visual pathway could influence proper sensory processing. Consistent with this, recent studies show that PD patients with visual hallucinations have low occipital GABA concentrations ([@B34]), and complex visual hallucinations in DLB are associated with altered GABAergic synaptic activity ([@B56]), which further supports the view that dysregulation of GABAergic system is involved in the visual pathway of PD ([**Figure 1C**](#f1){ref-type="fig"}). Whether this system is affected in the retina and visual cortex of all PD patients, and from early stages, remains to be determined.

Cognitive Dysfunction and GABAergic Signaling in Frontostriatal Circuits {#s5}
========================================================================

Cognitive manifestations are frequently reported in PD, with a prevalence of 20--25% for mild cognitive impairment and 30% for dementia. It is estimated that PD patients have a 3- to 6-fold higher risk of developing dementia than age-matched controls ([@B91]). Cognitive dysfunction is thought to be one of the key premotor manifestations of PD. At diagnosis, 15--20% of PD patients have mild cognitive impairment ([@B2]) and several studies in patients with iRBD have identified cognitive disturbances, including delayed verbal memory, poorer decision-making, worse attention and slower processing speed, these domains being predictive of future risk of developing PD or DLB ([@B27]; [@B93]; [@B104]; [@B39]). Thus, early onset cognitive abnormalities are mainly dependent on the frontal lobe ([@B31]; [@B66]; [@B86]; [@B19]).

Despite the evidence of neuropathological abnormalities in frontal brain areas in PD, their molecular and cellular alterations are poorly understood. Several studies have suggested that cognitive impairment in PD is attributable to neurotransmitter dysregulation rather than frank neurodegeneration ([@B55]; [@B80]). Dopamine and acetylcholine deficiencies in frontostriatal pathways play a major role in cognitive impairment in PD, but the contribution of the other neurotransmitter systems remains less certain. Regarding the role of GABA, in frontal cortex global transcriptional changes of GABAergic neurotransmission have been observed in DLB patients ([@B85]). It has also been shown that mRNA expression of the GABA-synthesizing enzyme glutamic acid decarboxylase-67 (GAD67) ([@B61]) and the calcium-binding protein parvalbumin (PV) ([@B60])---two key markers of GABAergic cells---is low in the dorsolateral prefrontal cortex of PD patients without evidence of cell loss, further suggesting the downregulation of inhibitory neurotransmission in the frontal cortex ([**Figure 1C**](#f1){ref-type="fig"}). In basal ganglia, *in vivo* GABA concentration changes have been detected in PD patients performing cognitive tasks ([@B18]). Interestingly, boosting GABAergic neurotransmission by zolpidem administration in early stage PD patients modulates aberrant beta-frequency oscillations ([@B41]), and the desynchronization of low-frequency activity seems to restore cognitive functions ([@B42]). Although these findings point towards decreased GABAergic activity in frontostriatal circuits in PD and DLB, whether GABAergic neurotransmission is also perturbed in premotor stages of PD has not been established, and its contribution to cognitive dysfunction needs to be elucidated in future studies.

GABA in Anxiety and Depression {#s6}
==============================

Anxiety and depression are common non-motor symptoms of PD, with reported prevalence rates of 20--40% ([@B20]) and 50% ([@B81]), respectively, and may precede motor signs ([@B51]). Notably, RBD patients score worse on anxiety and depression scales than controls and even PD patients ([@B11]). Although the exact neurobiological mechanisms that underlie anxiety and depression have not been fully elucidated, they seem to be intrinsically interrelated.

Pharmacological studies in both humans and animals have revealed that positive modulators of GABA~A~ receptors are anxiolytic and antidepressant, whereas negative modulators produce anxiogenic and depressive-like effects ([@B53]; [@B67]). Agents that enhance GABA~A~ receptor conductance (e.g., benzodiazepines) and GABA metabolism (e.g., valproate, vigabatrin, and tiagabine) exert anxiolytic effects, and it seems that partial agonists of α~2~/α~3~ GABA~A~ receptors, such as TPA-023, may also serve as antidepressants ([@B67]). Furthermore, genetic studies implicate GABA-receptor dysfunction in the risk of developing anxiety and depression ([@B53]). Recent evidence suggest that somatostatin contributes to the pathology of anxiety and depression ([@B35]; [@B29]), levels of this GABAergic marker being low in cerebrospinal fluid and induced pluripotent cells of PD patients ([@B25]; [@B50]). Nonetheless, there is still a lack of studies exploring the role of somatostatin in anxiety and depressive disorders in PD.

Gastrointestinal Symptoms and GABA Signaling in the Enteric Nervous System {#s7}
==========================================================================

Gastrointestinal disturbances fall within the spectrum of autonomic manifestations of PD patients. Hypersalivation, dysphagia, nausea, gastroparesis, small intestinal dysfunction, slow transit constipation and defecatory dysfunction have been attributed to α-synuclein-mediated small fiber neuropathy of the enteric nervous system (ENS) and to the neurodegeneration of the enteric branches of the vagus nerve in the brainstem ([@B74]). Among the gastrointestinal symptoms, constipation is the most frequent manifestation in PD and recent evidence suggests that it might also be one of the most common disturbances in prodromal PD ([@B90]). A multicenter study of 318 patients with polysomnography-confirmed iRBD concluded that they had substantially more autonomic symptoms than controls (SCOPA-AUT questionnaire), gastrointestinal symptoms being the most prominent domain ([@B32]). Nonetheless, gastric emptying measured with the 13C‐octanoate breath test showed that only drug‐naïve and early‐stage Parkinson's disease patients had delayed gastric emptying, authors suggesting that changes in structures modulating gastric motility might not be sufficiently severe in iRBD ([@B97]).

The last three decades have seen an expansion in the literature on the role of GABA in the control of gastrointestinal function, including mobility and inflammatory responses ([@B9]; [@B10]). GABA has been identified as an important modulator of gastrointestinal tract function. This neurotransmitter can stimulate or inhibit the enteric neurons acting though GABA~A~ or GABA~B~ receptors ([@B9]). Its role is particularly important in the colon, where it modulates the peristatic reflex. On the other hand, enteric inflammation occurs in PD and has been related to the initiation and progression of the disease ([@B46]). Nonetheless, it has yet to be determined why the production of pro-inflammatory cytokines takes place in the enteric tract. The purinergic system controls enteric inflammation, but GABA also has a major role in immune cell activity and inflammatory events in the gastrointestinal tract ([@B52]). Topiramate---an anti-epileptic drug that acts as a GABA~A~ agonist---reduces gastrointestinal inflammation in rats ([@B24]), identifying GABA as a putative neuroimmune modulator. A better understanding of the relationship of GABA signaling with intestinal motility and inflammation is necessary, however, to reveal a possible functional link between this neurotransmitter, the ENS, and gastrointestinal symptoms of PD.

Final Remarks and Conclusions {#s8}
=============================

Current evidence supports the view that PD is a degenerative disorder that affects multiple systems and presents with several non-motor symptoms. Over recent years, the importance of early, non-motor manifestations of PD has been increasingly recognized, as they may help to identify patients at high risk of developing α-synucleinopathies. Even though the neuronal circuits for motor symptoms are fairly well understood, the pathophysiological mechanisms for perceptual, cognitive, mood and autonomic disturbances of PD remain unclear.

Here, we report evidence consistent with the view that the GABAergic system is altered in PD and may contribute to non-motor symptoms that appear early in disease progression. Nonetheless, the literature in this field is dominated by non-placebo controlled and *postmortem* studies, generally based on small series and providing low-level evidence. To summarize, based on current findings, PD patients in premotor stages have anxiety and depression and alterations in the olfactory system, visual perception and visuospatial abilities, frontostriatal-related cognition, and gastrointestinal function. The neurobiological correlates of these deficits are unclear, in part because of the complex dynamic interactions between several neurotransmitter systems. Still, the dysfunction of GABAergic neurons in ventral medullary reticular formation seems to be linked to RBD. Moreover, preclinical studies show the relevance of interneurons in odor detection and the causal role of GABA in anxiety and depressive disorders, but we are far from establishing whether this also occurs in PD. On the other hand, disturbance of GABA signaling by pharmacological compounds affects visual processing and cognition, and GABA levels in the visual cortex are low in PD patients with visual hallucinations. It has been also shown that GABA controls gastrointestinal function, although it is not known whether this is associated with the gastrointestinal symptoms reported by PD patients. All these findings suggest that intervening in GABAergic signaling might modulate non-motor manifestations of PD and provide a novel avenue for non-dopaminergic therapy.

Nevertheless, there is a paucity of replication and large case-control studies. Future research should include *in vivo* longitudinal studies that examine the link between alterations in the GABAergic system and early non-motor symptoms by exploiting advances in PET ligands, magnetic resonance spectroscopy and CSF biomarkers. Preclinical studies might help to investigate the effects of GABA in the pathogenesis of non-motor symptoms, but we suggest that identifying the neurotransmitter deficits that correlate with clinical severity should be the mainstay for guiding future treatment studies.
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